B
Biohaven
Pioneering transformative treatments for neuroscience and immunology disorders
At a glance
- Status
- Listed
- Listing
- IPO 2017
Open roles
Biohaven in the New Haven ecosystem
The Biohaven office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- PBPortage Biotech
Series A5 investors entered at this stage
- RCRock Springs Capital
Venrock
RA Capital Management- ACAisling Capital
Vivo Capital
Series B and later1 investor entered at this stage
- YUYale University
Source: Dealroom Talent Intelligence.
Global footprint
Patents
66 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Biohaven was the backer or acquirer, 2016–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Biohaven's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Biohaven's portfolio, mapped.
See Biohaven on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
FDA accepts Biohaven's resubmitted Vyglxia (troriluzole) NDA for spinocerebellar ataxia
Biohaven licenses IgG degrader portfolio to Ono for Japan and select Asian markets
